spacer
home > epc > Autumn 2002
PUBLICATIONS

European Pharmaceutical Contractor

epc
Autumn 2002
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EPC provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of EPC
   
Text
PDF
bullet
introduction
In his Editor's Letter, Dr Graham Hughes reviews the articles in this Autumn issue of EPC  
view
bullet
Marketplace & Business
Regulators may be placed in a difficult position regarding the approval of new drugs where the majority of the dossier comprises of foreign clinical data. Carly Anderson and Faiz Kermani of CMR International debate this issue, in Global Acceptability of Clinical Data - Fact or Fiction?

 
view
In Mergers - Not the Only Way to Grow, John Morris, Head of KPMG's European Pharmaceutical Practice, discusses a likely slowdown in major merger and acquisition activity in the near future and suggests that companies look to other opportunities in order to grow  
view
Ben Coppin, Chief Operating Officer of Envisional Limited, outlines the recent increase in the illegal sale of prescription drugs online, in A Call to Regulate the Online Sale of Prescription Drugs  
view
Geoff Parker, Director of Scimcon, highlights the causes of the lab information mountain and offers tips on how to conquer it, in Information Overload  
view
In In Search of the Organisation?, Dr Flic Gabbay, Director of Strategic Projects at Micron Research, considers the redefinition of corporate culture in outsourced networks  
view
bullet
Clinical Trials
Wireless technology offers a safe and effective method of revolutionising the industry by helping to speed up the trial process. Richard Hanscott, Vice-President of Business Solutions at Orange UK, reflects on recent advances, in The Future of Wireless Technologies in Clinical Drug Trials  
view
Dr Milen Vrabevski, Medical Director at Comac Medical, continues his investigation of the advantages and potential pitfalls for multinational pharmaceuticals operating in emerging scientific markets, in part two of Clinical Trials in Bulgaria  
view
In Increasing Trial Performance Through Replicated System Technology, Eli Hauser, Executive Director Strategic Programs at Phase Forward Incorporated, looks at how EDC systems for trial data collection and management have heightened demand for access to the clinical trial database and increased our sensitivity to site connectivity and usability concerns  
view
Philip Guard, Vice-President of European Operations at Clinimetrics Research Associates Inc, explores Moving Through Clinical Phases II and III and considers the implications of decision-making and communication at each stage  
view
bullet
Legal & Regulatory
Regulatory genetic toxicology testing produces between 20 and 25 per cent in vitro positive results year on year. Jon Kitching from the Department of Experimental Biology at Huntingdon Life Sciences, examines the Comparison of the Regulatory Ames Test with the SOS/umu Assay as Part of Lead Optimisation Screening  
view
In CRO Selection - A Process Revisited, Sherif Odaranile, Clinical Auditor at ADAMAS Consulting, suggests how best to structure a sponsor's outsourcing teams to maximise returns on investment  
view
Aggressive tax regulations have already forced multinational pharmaceutical companies to consider the tax implications of their transfer pricing arrangements. However, Dr Edward Keen, Senior Director, Transfer Pricing at KPMG UK considers the non-tax implications, in The Importance of Transfer Pricing to Pharmaceutical Contracting Companies  
Ruth Paul, Regulatory Manager at Simbec Research Ltd, discusses The Role of the EU National Agencies in European Regulatory Affairs and comments that despite harmonised EU regulatory procedures, the working methods of the individual agencies in member states still have a long way to go  
view
bullet
Drug Discovery, Development & Delivery
In Drug Interactions: Implications for Pharmacogenetics in Drug Development, Dr Rashmi Shah, Senior Medical Officer at the Medicines Control Agency, highlights the perils of drug-drug interactions that afflict many drugs during routine clinical use  
view
The timing of the development of lipodystrophy will have an impact on the potential market sales of a therapeutic drug. Dheeraj Khiytani, HIV Analyst at Datamonitor, explores the implications, in Fat Redistribution in HIV Patients - An Opportunity for Drug Manufacturers?  
view
bullet
e-Data
In Novel Use of Interactive Voice Response Systems in the Measurement of Clinical Endpoint Data in CNS Studies, Dr Bill Byrom at ClinPhone Group Ltd, and Dr John Greist of Healthcare Technology Systems, explore the more novel uses of IVR when measuring clinical endpoint data and the extension of this methodology as a pre-screening patient qualification tool  
view
Dr Thomas Bart, Managing Director of e-Clinical Research GmbH, provides a short overview of the current practice and possible future developments in clinical research electronic data capture, in EDC: Quo Vadis?  
view
EDC tools would seem to be the perfect antidote for problems posed within the clinical trials industry. In Making EDC Work for You, Kate Foster, Associate Director, Global Client Services for CB Technologies, presents the pros and cons of incorporating EDC  
In Integrating Document Management and Content Management Systems in the Pharmaceutical Industry, David Gingell, Marketing Director, EMEA at Documentum Inc, highlights a market under pressure and explains that content management can contribute significantly to easing some of the tension surrounding speeding time to market  
Mike Nell, Technical Director and Mark Wren, eService Director at Phase Forward Incorporated, offer some advice on honing your competitive edge, in How to Get Ahead in Electronic Data Capture  
bullet
Science & Innovation
If the dream of proteomics is the identification and characterisation of all proteins, then the nightmare is the number of unique functional protein structures. Dr Lucio van Rooijen, Vice President Business Development, and Dr Josef Schwarz, Director of Protein Profiling at Xzillion, examine the Ongoing Challenges in Proteomics  
The LIMS arena has experienced some headline changes recently and a keen awareness of the implications of these could prove invaluable in assessing both the system and the vendor. John Dickson, Consultant at Thermo LabSystems outlines a vendor's perspective, in What's New in LIMS?  
view
Thomas Allen, Director of Allen Preclinical Consultants GmbH discusses bridging the gap between the pharmaceutical and preclinical CRO industries, in Perspectives in Preclinical Development  
view
bullet
LABS & Logistics
Regulatory changes in the transportation of infectious substances profoundly impact many health care sectors. David Cocker of MDCPartners considers the impact of these changes, in A Different Strategy in a Changing World of Infectious Substances  
view
bullet
Review
Julia Lloyd-Parks, Senior Consultant at Technomark Consulting Services Ltd, reviews the 38th Annual Meeting of The Drug Information Association, Chicago, which took place in June  
view
   
spacer



Published quarterly in
February, May,
August and November

News and Press Releases

Bigneat is awarded the Queen’s Award by Lord-Lieutenant of Hampshire

Bigneat Ltd, winner of a Queen’s Award for Enterprise earlier this year, received their Award from Nigel Atkinson Esq, HM Lord-Lieutenant of Hampshire on 16th October at the Bigneat factory in Waterlooville.
More info >>

White Papers

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

Synergy Research Group

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible. In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter – MMCTs)
More info >>

Industry Events

Pharma Packaging and Labeling East Coast 2018

21-22 February 2018, Philadelphia, USA

The 10th Annual Pharma Packaging and Labeling East Coast event aims to create an environment where commercial packaging and labeling teams work together to successfully manage both creative and regulatory demands while safeguarding products and protecting patients.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement